- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
GREENSBORO, N.C. — Merz Pharmaceuticals has created two programs to provide financial assistance to patients using its drug for cervical dystonia, the company said Tuesday.
The programs — the Xeomin patient co-payment program and the Xeomin patient assistance program — cover Xeomin (incobotulinumtoxinA), designed to decrease the severity of abnormal head positions and neck pains in patients with the disease, which causes muscle contractions resulting in repetitive movements and abnormal postures.
“By offering a continuum of Xeomin financial assistance programs, our hope is to help patients manage their cervical dystonia and blepharospasm costs by reducing or eliminating financial obstacles that may prevent initiation or continuation of treatment,” said Merz president and CEO Jack Britts.